Padda SK - Search Results

1

Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.

Jeong Y, Hellyer JA, Stehr H, Hoang NT, Niu X, Das M, Padda SK, Ramchandran K, Neal JW, Wakelee H, Diehn M. Jeong Y, et al. Among authors: padda sk. Clin Cancer Res. 2020 Jan 1;26(1):274-281. doi: 10.1158/1078-0432.CCR-19-1237. Epub 2019 Sep 23. Clin Cancer Res. 2020. PMID: 31548347 Free PMC article.

2

Complications of ablative therapies in lung cancer.

Padda S, Kothary N, Donington J, Cannon W, Loo BW Jr, Kee S, Wakelee H. Padda S, et al. Clin Lung Cancer. 2008 Mar;9(2):122-6. doi: 10.3816/CLC.2008.n.019. Clin Lung Cancer. 2008. PMID: 18501100

3

A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.

Clément-Duchêne C, Krupitskaya Y, Ganjoo K, Lavori P, McMillan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD, Wakelee HA. Clément-Duchêne C, et al. J Thorac Oncol. 2010 Nov;5(11):1821-5. doi: 10.1097/JTO.0b013e3181f1d23c. J Thorac Oncol. 2010. PMID: 20881641 Free PMC article. Clinical Trial.

4

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.

Padda SK, Krupitskaya Y, Chhatwani L, Fisher GA, Colevas AD, San Pedro-Salcedo M, Decker R, Latz JE, Wakelee HA. Padda SK, et al. Cancer Chemother Pharmacol. 2012 Apr;69(4):1013-20. doi: 10.1007/s00280-011-1792-8. Epub 2011 Dec 11. Cancer Chemother Pharmacol. 2012. PMID: 22160298 Free PMC article. Clinical Trial.

5

Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer.

Riess JW, Logan AC, Krupitskaya Y, Padda S, Clément-Duchêne C, Ganjoo K, Colevas AD, Pedro-Salcedo MS, Kuo CJ, Wakelee HA. Riess JW, et al. Cancer Invest. 2012 Mar;30(3):231-5. doi: 10.3109/07357907.2012.656862. Cancer Invest. 2012. PMID: 22360362 Clinical Trial.

6

Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.

Padda SK, Chhatwani L, Zhou L, Jacobs CD, Lopez-Anaya A, Wakelee HA. Padda SK, et al. Anticancer Drugs. 2013 Aug;24(7):731-5. doi: 10.1097/CAD.0b013e32836100d7. Anticancer Drugs. 2013. PMID: 23552470 Clinical Trial.

7

A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.

Riess JW, Padda SK, Bangs CD, Das M, Neal JW, Adrouny AR, Cherry A, Wakelee HA. Riess JW, et al. Among authors: padda sk. Clin Lung Cancer. 2013 Sep;14(5):592-5. doi: 10.1016/j.cllc.2013.04.008. Epub 2013 Jun 27. Clin Lung Cancer. 2013. PMID: 23810364 Free PMC article. No abstract available.

8

Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy.

Padda SK, Burt BM, Trakul N, Wakelee HA. Padda SK, et al. Semin Oncol. 2014 Feb;41(1):40-56. doi: 10.1053/j.seminoncol.2013.12.011. Epub 2013 Dec 12. Semin Oncol. 2014. PMID: 24565580 Review.

9

Diffuse high intensity PD-L1 staining in thymic epithelial tumors.

Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelee HA. Padda SK, et al. J Thorac Oncol. 2015 Mar;10(3):500-8. doi: 10.1097/JTO.0000000000000429. J Thorac Oncol. 2015. PMID: 25402569 Free PMC article.

10

Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.

Liang Y, Padda SK, Riess JW, West RB, Neal JW, Wakelee HA. Liang Y, et al. Among authors: padda sk. Lung Cancer. 2015 Jan;87(1):34-8. doi: 10.1016/j.lungcan.2014.11.006. Epub 2014 Nov 15. Lung Cancer. 2015. PMID: 25443273

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

72 results

Search Page